company background image
4587 logo

PeptiDream TSE:4587 Stock Report

Last Price

JP¥2.01k

Market Cap

JP¥261.0b

7D

-6.2%

1Y

56.5%

Updated

06 Feb, 2025

Data

Company Financials +

4587 Stock Overview

A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. More details

4587 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance6/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

PeptiDream Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PeptiDream
Historical stock prices
Current Share PriceJP¥2,014.00
52 Week HighJP¥3,060.00
52 Week LowJP¥1,242.00
Beta0.47
1 Month Change-19.47%
3 Month Change-28.03%
1 Year Change56.49%
3 Year Change-2.04%
5 Year Change-63.51%
Change since IPO180.21%

Recent News & Updates

Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?

Dec 22
Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?

PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest

Nov 21
PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest

Recent updates

Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?

Dec 22
Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?

PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest

Nov 21
PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest

PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Nov 18
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Is PeptiDream (TSE:4587) Using Too Much Debt?

Nov 15
Is PeptiDream (TSE:4587) Using Too Much Debt?

PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings

Oct 31
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings

Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?

Oct 15
Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?

PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate

Aug 29
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate

PeptiDream Inc. Just Beat Revenue Estimates By 13%

Aug 12
PeptiDream Inc. Just Beat Revenue Estimates By 13%

PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Jun 30
PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

Jun 02
News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues

Apr 30
PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues

Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?

Apr 29
Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Shareholder Returns

4587JP BiotechsJP Market
7D-6.2%-3.3%-1.1%
1Y56.5%15.6%6.4%

Return vs Industry: 4587 exceeded the JP Biotechs industry which returned 15.6% over the past year.

Return vs Market: 4587 exceeded the JP Market which returned 6.4% over the past year.

Price Volatility

Is 4587's price volatile compared to industry and market?
4587 volatility
4587 Average Weekly Movement6.4%
Biotechs Industry Average Movement8.7%
Market Average Movement3.5%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market1.9%

Stable Share Price: 4587's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: 4587's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
2006735Patrick Crawford Reidwww.peptidream.com

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.

PeptiDream Inc. Fundamentals Summary

How do PeptiDream's earnings and revenue compare to its market cap?
4587 fundamental statistics
Market capJP¥261.04b
Earnings (TTM)JP¥17.11b
Revenue (TTM)JP¥47.77b

15.3x

P/E Ratio

5.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4587 income statement (TTM)
RevenueJP¥47.77b
Cost of RevenueJP¥12.24b
Gross ProfitJP¥35.53b
Other ExpensesJP¥18.41b
EarningsJP¥17.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)132.05
Gross Margin74.37%
Net Profit Margin35.83%
Debt/Equity Ratio34.7%

How did 4587 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 18:55
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PeptiDream Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Akinori UedaGoldman Sachs